treatment group – Page 4 – Communicable Diseases Research

The effects of text reminders on the use of family planning services: evidence from a randomised controlled trial in urban Mozambique

Randomized Controlled Trial

Published on 2022-04-012022-10-05
Journal: BMJ Global Health [Category] 임상,

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Randomized Controlled Trial

Published on 2022-04-012022-10-04
Journal: Clinical microbiology and infection : the official [Category] 신약개발, 임상,

[키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome Admissions adverse events assigned clinical clinical recovery clinical trial coronavirus coronavirus disease COVID-19 did not reduce double-blind double-blinded enrolment evaluate Favipiravir hazard ratio Hospital admission Hospitalization intensive care interim analysis interquartile range male matching placebo median age median time Mild mild case mild COVID-19 mild COVID-19 patient monitoring board multicentre negative RT-PCR no difference Non-severe SARS-CoV-2 Non-severe SARS-CoV-2. participant Patient PCR test PCR-confirmed Placebo placebo-controlled clinical trial placebo-controlled trial Primary outcome Randomized receive recruited reduce reducing SARS-CoV-2 Saudi Arabia secondary outcome Seven severe adverse events symptom resolution the placebo group therapy Treatment treatment group Trial two group viral clearance
[DOI] 10.1016/j.cmi.2021.12.026 PMC 바로가기 [Article Type] Randomized Controlled Trial

Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital

Observational Study

Published on 2022-04-012022-10-04
Journal: Journal of medical virology [Category] Fulltext, MERS, 임상,

[키워드] acute respiratory syndrome addition adjust Analysis benefit clinical care clinical outcomes comparison confounders control group coronavirus COVID-19 Day dose Effectiveness Efficacy group hospital Hospital stay hospitalized patient ICU ICU admission in vitro in-hospital mortality inhibit intensive care intubation rate Ivermectin ivermectin group ivermectin treatment maintain mechanical ventilation Mortality multivariable logistic regression not significantly different outcome patients with COVID-19 propensity score matching Prospective Study PSM Replication safety profile SARS-CoV-2 SARS-CoV-2 replication significantly higher treatment group was used with COVID-19
[DOI] 10.1002/jmv.27469 PMC 바로가기 [Article Type] Observational Study

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Clinical Trial

Published on 2022-04-012022-10-04
Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, 치료법,

[키워드] 1:1 A significant reduction all-cause mortality assigned Baricitinib baseline Blood clots Brazil cardiovascular event Care Cohort Combination company conducted Corticosteroids Critically ill death died double-blind duration of hospitalisation Efficacy efficacy analysis Efficacy and safety Endpoint enrolled evaluate event exploratory extracorporeal membrane oxygenation hazard ratio hospital hospitalised hospitalised patient infections inhibitor intention-to-treat population Invasive mechanical ventilation investigator Janus kinase laboratory-confirmed SARS-CoV-2 infection less Lilly membrane Mortality not differ participant Participants Patient Phase 3 phase 3 trial Placebo placebo-controlled trial placebo-treated participant prevented randomised Randomly receiving reduced reduction Registered risk reduction safety analysis safety population SARS-COV-2 infection selective severely ill patient shown significantly significantly shorter Standard Standard of care Study design study group study population systemic corticosteroid the placebo group Time to recovery Treatment treatment group treatment groups Trial USA ventilator-free day Ventilator-free days was done with COVID-19
[DOI] 10.1016/S2213-2600(22)00006-6 PMC 바로가기 [Article Type] Clinical Trial

Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice

K18-hACE2 형질전환 마우스에서 우려되는 알파, 베타 및 델타 SARS-CoV-2 변이체에 대한 항체 매개 보호 평가

Article

Published on 2022-03-232022-09-11
Journal: Journal of Virology [Category] MERS, SARS, 변종, 진단, 치료법,

[키워드] Alpha Alpha VOC angiotensin angiotensin converting enzyme Beta Brain can be used concern convalescent convalescent plasma COVID-19 COVID-19 pandemic COVID-19 patient Critically ill decrease Delta Delta VOC disease dose Efficacy elevated enzyme evaluate Evaluating hACE2 hcp Human IgG titer immune evasion immunization in vivo model K18 K18-hACE2 K18-hACE2 transgenic mice lethality lung Mediated mice modeling modeling COVID-19 monoclonal antibody Mortality not decreased nucleocapsid nucleocapsid IgG pandemic passive immunity passive immunization polyclonal antibodies polyclonal antibody problem protection RBD Receptor binding domain response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants serum single dose Strains survival These data transgenic Transgenic mouse Treatment treatment group Vaccine variants variants of concern Viral Viral RNA while
[DOI] 10.1128/jvi.02184-21 PMC 바로가기 [Article Type] Article

Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II

Randomized Controlled Trial

Published on 2022-03-072022-10-04
Journal: Stem Cell Research & Therapy [Category] MERS, SARS, 임상,

[키워드] 1:1 acute phase reactant Adverse adverse effect adverse event Allogeneic analyzed C-reactive protein caused CD4 CD8 chest imaging clinical symptom clinical trial control group COVID-19 Cytokine storm D-dimer declined demonstrated double-blind downregulation duration of hospitalization Efficacy Enrollment evaluate events ferritin FIVE GMP hospitalized patient hypoxia immune immune system increase in inflammatory lung disease injection intravenous infusion Intubated Laboratory parameters lymphocyte Lymphocyte count lymphopenia mechanism menstrual blood Menstrual blood stromal cells Mesenchymal stromal cell modulate MSCs New treatment outcomes Oxygen level Patient patients Phase I Placebo placebo-controlled clinical trial pulmonary involvement Randomized reduction Registered Result Safety safety endpoint SARS-CoV-2 Secretome severe COVID-19 Significant significantly stromal cell suppress survival rate survivor therapy treat treated Treatment treatment group Volume
[DOI] 10.1186/s13287-022-02771-w PMC 바로가기 [Article Type] Randomized Controlled Trial

Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

Covid-19 증후군.COVID-19 후 지속적인 증상이있는 환자의 혈장, 대변 및 소변에서 SARS-COV-2 RNA 검출

Research Article

Published on 2022-03-032022-09-10
Journal: BMC Infectious Diseases [Category] MERS, SARS, 유전자 메커니즘, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antiviral treatment benefit blood tests Chain Reaction Clinical data Cohort cohort of patient collected compassionate use conducted constellation coronavirus COVID-19 COVID-19 patient detectable diagnosed with COVID-19 Diagnosis dysfunction Dyspnea evaluated explain fatigue Fever functional functional capacity Functional status Hypothesis immune activation immunological improvement inflammatory markers knowledge Mild Most patients muscle pain offered outcome Pain Patient patients performed physiopathological mechanism plasma polymerase chain polymerase chain reaction positive positive RT-PCR reduced rehabilitation reported respiratory Result reverse transcription reverse transcription polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 RNA detection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significant difference significant differences Stool subjects Symptom Symptomatic treatment Symptoms syndrome Tachycardia therapeutic option treatment group Urine Viral viral persistence
[DOI] 10.1186/s12879-022-07153-4 PMC 바로가기 [Article Type] Research Article

Effect of single session receptive music therapy on anxiety and vital parameters in hospitalized Covid-19 patients: a randomized controlled trial

Article

Published on 2022-02-242022-10-04
Journal: Scientific Reports [Category] 임상, 치료법,

Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study

Article

Published on 2022-02-032022-10-04
Journal: Scientific Reports [Category] 바이오마커,

[키워드] 95% CI adverse event all-cause mortality Analysis Aneurysm anticipated aortic aneurysm ARDS baseline blocked with CD73 cluster of differentiation concerning concomitant use congestive heart failure D30 death demonstrated diagnosed double-blind drug-drug interaction Efficacy and safety exclusion criteria glucocorticoid Hemorrhagic IFN IMPROVE induction initial interim analysis intestinal intravenous Ischemia Liver cirrhosis Major malignant disease matching placebo mechanism Neutralizing antibodies neutralizing antibody outcome outcome measure parallel group Patient Placebo placebo-controlled study postoperative Prevent Pyrexia Randomized randomized patient Registered renal replacement therapy reported serum Shock statistically significant difference suggested surgery survival survived treated Treatment treatment group Trial up-regulating
[DOI] 10.1038/s41598-022-05771-1 PMC 바로가기 [Article Type] Article

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy

BNT162b2 백신 후 다발성 경화증 환자의 Anti-Spike IgG: 이탈리아의 탐색적 사례 대조 연구

Multicenter Study

Published on 2022-02-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] adverse event AEs analyzed anti-spike antibodies antibodies antibody blood sample Blood samples BNT162b2 case-control study Clinical efficacy collected Community Comparisons condition Control COVID-19 COVID-19 vaccine described detect Disease-modifying therapies enrolled evaluated exploratory first dose HCW HCWs healthcare worker IgG Immunosuppressant immunosuppressants implication interquartile range IQR Italy median median and interquartile range Mild mild to moderate moderate multicenter Multiple multiple sclerosis observation Ocrelizumab of BNT162b2 one patient other treatment other treatments Patient patients patients treated performed Pfizer Pfizer-BioNTech receive receiving reduce reduced reported resolved respond scrutiny serological response severity the vaccine therapy treated treated patient treated patients Treatment treatment group vaccination vaccine dose Vaccine, BNT162b2. Vaccines Wilcoxon-Mann-Whitney
[DOI] 10.1016/j.msard.2021.103415 PMC 바로가기 [Article Type] Multicenter Study